Amendments to the Claims:

Please cancel claim 63 without prejudice.

Please amend claims 1-62 as follows.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for ~~treatment of~~ treating abnormal cells in a mammal~~, the method~~ comprising ~~treating~~ administering to the mammal ~~with~~ an effective amount of virus selected from echo viruses, and modified forms and combinations thereof, which ~~recognise~~ recognize $\alpha_2\beta_1$ for infectivity of the cells such that at least ~~some~~ one of the cells are killed by the virus.

2. (Currently Amended) [[A]] The method according to claim 1 further comprising subjecting the mammal to ~~a number of treatments~~ more than one treatment with the virus, and wherein the virus in each of the treatments is the same or different.

3. (Currently Amended) [[A]] The method according to claim 1 wherein the virus comprises an echovirus serotype or a modified form thereof.

4. (Currently Amended) [[A]] The method according to claim 3 wherein the virus is ~~selected from the group consisting of~~ EV1 ~~and~~ or EV8.

5. (Currently Amended) [[A]] The method according to claim 3 wherein the virus is a modified echovirus.

6. (Currently Amended) [[A]] The method according to claim 5 wherein the virus has been modified to enhance ability of the virus to infect the abnormal cells.

7. (Currently Amended) [[A]] The method according to claim 5 ~~or 6~~ wherein the modified echovirus is a modified form of ~~an echovirus selected from a group consisting of~~ EV1 ~~and~~ or EV8.

8. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 1 ~~to 7~~ wherein the virus is administered to the mammal in combination with a ~~further~~ second virus which infects the abnormal cells.

9. (Currently Amended) [[A]] The method according to claim 8 wherein the abnormal cells express ICAM-1 and the ~~further~~ second virus ~~recognises~~ recognizes ICAM-1 for infectivity of the abnormal cells.

10. (Currently Amended) [[A]] The method according to claim 9 wherein the ~~further~~ second virus is a Coxsackievirus or a modified form thereof.

11. (Currently Amended) [[A]] The method according to claim 10 wherein the Coxsackievirus is a Coxsackievirus serotype selected from A13, Al 5, Al 8 and A21.

12. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 1 ~~to 11~~ wherein the abnormal cells are cancer cells.

13. (Currently Amended) [[A]] The method according to claim 12 wherein the cancer cells are ~~cells of a cancer selected from a group consisting of~~ ovarian cancer cells, melanoma cells, prostate cancer cells, breast cancer cells, pancreatic cancer cells, colon cancer cells ~~and~~ or colorectal cancer cells, or are cells that have spread from ovarian cancer, melanoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer or colorectal cancer.

14. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 1 ~~to 13~~ wherein the abnormal cells have up-regulated expression of $\alpha_2\beta_1$.

15. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 1 ~~to 14~~ wherein the virus is administered topically, systemically or intratumorally to the mammal.

16. (Currently Amended) A method of screening a sample of abnormal cells from a mammal for susceptibility to virus induced cell death to evaluate administering virus to the mammal for treatment of the abnormal cells, the method comprising:

~~(a) providing the sample of the abnormal cells;~~

([[b]]a) ~~treating~~ contacting the cells with ~~the~~ a virus for a period of time sufficient to allow infection of the cells by the virus; and

([[c]]b) determining whether the virus has infected the cells and caused death of at least ~~some~~ one of the abnormal cells;

wherein the virus is selected from echo viruses, and modified forms and combinations thereof, which ~~recognise~~ recognize $\alpha_2\beta_1$ for infectivity of the abnormal cells.

17. (Currently Amended) [[A]] The method according to claim 16 wherein the virus ~~comprises~~ is an echovirus serotype or a modified form thereof.

18. (Currently Amended) [[A]] The method according to claim 16 wherein the virus is ~~selected from a group consisting of~~ EV1 ~~and~~ or EV8.

19. (Currently Amended) [[A]] The method according to claim 17 wherein the virus is a modified echovirus.

20. (Currently Amended) [[A]] The method according to claim 19 wherein the virus has been modified to enhance ability of the virus to infect the abnormal cells.

21. (Currently Amended) [[A]] The method according to claim 19 ~~or 20~~ wherein the modified echovirus is a modified form of ~~an echovirus selected from a group consisting of~~ EV1 ~~and~~ or EV8.

22. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 16 ~~to 21~~ further comprising comparing the ability of the virus to infect the cells and cause death of the cells, to ~~with a different~~ the ability of a second virus that recognizes $\alpha_2\beta_1$ for infectivity of the cells, subjected to steps ~~(b) and (c)~~ (a) and (b) ~~utilising~~ utilizing another sample of the cells, to infect the cells and cause death ~~and which recognises $\alpha_2\beta_1$ for infectivity~~ of the cells.

23. (Currently Amended) [[A]] The method according to claim 22 wherein the ~~different~~ second virus is a different echovirus or modified form thereof.

24. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 16 ~~to 23~~ wherein the cells are cancer cells.

25. (Currently Amended) [[A]] The method according to claim 24 wherein the cancer cells are ~~cells of a cancer selected from a group consisting of~~ ovarian cancer cells, melanoma cells, prostate cancer cells, breast cancer cells, pancreatic cancer cells, colon cancer cells ~~and~~ or colorectal cancer cells, or are cells that have spread from ovarian cancer, melanoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer or colorectal cancer.

26. (Currently Amended) A method of screening a virus for ability to infect and cause death of abnormal cells from a mammal to evaluate administering the virus to the mammal for treatment of the abnormal cells, the method comprising:

~~(a) selecting the virus;~~

([[b]]a) ~~treating~~ contacting ~~a sample of the~~ abnormal cells from the mammal with ~~the~~ a virus for a period of time sufficient to allow infection of the cells by the virus; and

([[c]]b) determining whether the virus has infected and caused death of at least ~~some~~ one of the abnormal cells;

wherein the virus is selected from echoviruses and modified forms thereof, which ~~recognise~~ recognize $\alpha_2\beta_1$ for infectivity of the abnormal cells.

27. (Currently Amended) [[A]] The method according to claim 26 wherein the virus ~~comprises~~ is an echovirus serotype or a modified form thereof.

28. (Currently Amended) [[A]] The method according to claim 26 wherein the virus is ~~selected from a group consisting of~~ EV1 ~~and~~ or EVS.

29. (Currently Amended) [[A]] The method according to claim 27 wherein the virus is a modified echovirus.

30. (Currently Amended) [[A]] The method according to claim 29 wherein the virus has been modified to enhance the ability of the virus to infect the abnormal cells.

31. (Currently Amended) [[A]] The method according to claim 29 ~~or 30~~ wherein the modified echovirus is a modified form of ~~an echovirus selected from a group consisting of~~ EV1 ~~and~~ or EV8.

32. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 26 ~~to 31~~ further comprising comparing ability of the virus to infect and cause death of the cells, to the ability of ~~with~~ a ~~different~~ second virus that recognizes $\alpha_2\beta_1$ for infectivity of the cells, subjected to steps ~~(b) and(c) utilising~~ (a) and (b) utilizing another sample of the cells, to infect the cells and cause death ~~and which recognizes $\alpha_2\beta_1$ for infectivity~~ of the cells.

33. (Currently Amended) [[A]] The method according to claim 32 wherein the ~~different~~ second virus is a different echovirus or modified form thereof.

34. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 26 ~~to 33~~ wherein the abnormal cells are cancer cells.

35. (Currently Amended) [[A]] The method according to claim 34 wherein the cancer cells are ~~cells of a cancer selected from a group consisting of~~ ovarian cancer cells, melanoma cells, prostate cancer cells, breast cancer cells, pancreatic cancer cells, colon cancer cells ~~and~~ or colorectal cancer cells, or are cells that have spread from ovarian cancer, melanoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer or colorectal cancer.

36. (Currently Amended) A method for inducing an immune response in a mammal against abnormal cells expressing $\alpha_2\beta_1$, the method comprising infecting abnormal cells in the mammal with a virus selected from the group consisting of echoviruses, ~~and~~ modified forms thereof, and combinations thereof, ~~whereby~~ thereby causing lysis of at least ~~some~~ one of the cells ~~is caused~~ and inducing an immune response in the mammal against the abnormal cells.

37. (Currently Amended) [[A]] The method according to claim 36 wherein the virus ~~comprises~~ is an echovirus serotype ~~of~~ or modified form thereof.

38. (Currently Amended) [[A]] The method according to claim 37 wherein the virus is ~~selected from the group consisting of~~ EV1 ~~and~~ or EV8.

39. (Currently Amended) [[A]] The method according to claim 37 wherein the virus is a modified echovirus.

40. (Currently Amended) [[A]] The method according to claim 39 wherein the virus has been modified to enhance ability of the virus to infect the abnormal cells.

41. (Currently Amended) [[A]] The method according to claim 39 ~~or 30~~ wherein the modified echovirus is a modified form of ~~an echovirus selected from a group consisting of~~ EV1 ~~and~~ or EV8.

42. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 36 ~~to 41~~ wherein the abnormal cells have up-regulated expression of $\alpha_2\beta_1$.

43. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 36 ~~to 42~~ wherein the virus is administered to the mammal in combination with a ~~further~~ second virus which infects the abnormal cells.

44. (Currently Amended) [[A]] The method according to claim 43 wherein the abnormal cells express ICAM-1 and the ~~further~~ second virus ~~recognises~~ recognizes ICAM-1 for infectivity of the abnormal cells.

45. (Currently Amended) [[A]] The method according to claim 44 wherein the ~~further~~ second virus is a Coxsackievirus or modified form thereof.

46. (Currently Amended) [[A]] The method according to claim 45 wherein the Coxsackievirus is a Coxsackievirus serotype selected from A13, A15, A18 and A21.

47. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 36 ~~to~~ 46 wherein the abnormal cells are cancer cells.

48. (Currently Amended) [[A]] The method according to claim 47 wherein the cancer cells are ~~cells of a cancer selected from a group consisting of~~ ovarian cancer cells, melanoma cells, prostate cancer cells, breast cancer cells, pancreatic cancer cells, colon cancer cells ~~and~~ or colorectal cancer cells, or are cells that have spread from ovarian cancer, melanoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer or colorectal cancer.

49. (Currently Amended) [[A]] The method according to ~~any one of~~ claim[[s]] 36 ~~to 48~~ wherein the virus is administered topically, systemically or intratumorally to the mammal.

50. (Currently Amended) A pharmaceutical composition for treating abnormal cells in a mammal, comprising an inoculant for generating virus to treat the cells such that at least ~~some~~ one of the cells ~~are~~ is killed by the virus, and ~~together with~~ a pharmaceutically acceptable carrier, wherein the virus recognizes $\alpha_2\beta_1$ for infectivity of the cells and is selected from echoviruses, ~~and~~ modified forms thereof, and combinations thereof~~, which recognise $\alpha_2\beta_1$ for infectivity of the cells~~.

51. (Currently Amended) [[A]] The pharmaceutical composition according to claim 50 wherein the virus ~~comprises~~ is an echovirus serotype or modified form thereof.

52. (Currently Amended) [[A]] The pharmaceutical composition according to claim 51 wherein the virus is ~~selected from the group consisting of~~ EV1 ~~and~~ or EV8.

53. (Currently Amended) [[A]] The pharmaceutical composition according to claim 49 wherein the virus is a modified echovirus.

54. (Currently Amended) [[A]] The pharmaceutical composition according to claim 51 wherein the virus has been modified to enhance ability of the virus to infect the abnormal cells.

55. (Currently Amended) [[A]] The pharmaceutical composition according to claim 53 ~~or 54~~ wherein the modified echovirus is a modified form of ~~an echovirus selected from a group consisting of~~ EV1 ~~and~~ or EV8.

56. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any one of~~ claim[[s]] 50 ~~to 55~~ wherein the abnormal cells are cancer cells.

57. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any one of~~ claim[[s]] 50 ~~to 56~~ wherein the pharmaceutical composition is for topical administration or injection.

58. (Currently Amended) An applicator for applying an inoculant to a mammal for generating a virus to treat abnormal cells in the mammal, wherein the applicator comprises a region impregnated with the inoculant ~~mammal such that the inoculant is in contact with the mammal~~, and the virus recognizes $\alpha_2\beta_1$ for infectivity of the cells and is selected from echoviruses, ~~and~~ modified forms thereof, and combinations thereof~~, which recognise $\alpha_2\beta_1$ for infectivity of the cells~~.

59. (Currently Amended) [[An]] The applicator according to claim 58 wherein the region impregnated with the ~~virus~~ inoculant comprises padding or wadding for ~~being held~~ holding the inoculant in contact with the mammal.

60. (Currently Amended) [[An]] The applicator according to claim 58 ~~or 59~~ wherein the abnormal cells are abnormal skin cells and the applicator further comprises one or more adhesive surfaces for adhering to skin of the mammal.

61. (Currently Amended) [[An]] The applicator according to ~~any one of~~ claim[[s]] 58 ~~to 60~~ wherein the region is in the form of a patch or sticking plaster.

62. (Currently Amended) ~~Use of an inoculant for generating virus in the manufacture of medicament~~ A method for inducing an immune response against abnormal cells in a mammal[[,]] comprising contacting the applicator of claim 58 with abnormal cells of a mammal, and allowing the virus to lyse at least one of the abnormal cells, thereby inducing an immune response against abnormal cells in the mammal ~~where the virus is selected from echovirus, and modified forms and combinations thereof, which recognize $\alpha_2\beta_1$ for infectivity of the abnormal cells~~.

63. (Canceled)